Hydrocodone Market Share

On the basis of geographical analysis, the hydrocodone market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the Europe industry is predicted to account for largest revenue share by 2036, propelled by advancements in the healthcare sector in the region.Moreover, the increasing investment in the medical research is estimated to further propel the market growth.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the rising cases of arthritis and other diseases, which requires pain killer drugs. According to the data by the Center for Disease Control and Prevention (CDC), about 58.5 million people, which is 23.7% of the total population in the United States, have doctor-diagnosed arthritis. Moreover, the liberty to research with narcotics for medicinal use, in developed countries, is anticipated to propel the hydrocodone market growth.

Frequently Asked Questions (FAQ)

The growing demand for hydrocodone-based painkillers is estimated to boost the market growth.

The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022 â€“ 2030.

Regulations regarding the use of narcotics, and the addictive nature of opioids, are estimated to hamper the market growth.

The market in the North America region is estimated to provide more business opportunities over the forecast period, owing to the favorable policies for research involving narcotics for medical use.

The major players in the market are Gilead Sciences, Inc., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Eli Lilly and Company, BioControl Medical, and others.

Hydrocodone Market Share